Recommended Chinese CDMO and CRO Resources for RNA and Nucleic-Acid Development
China’s RNA and nucleic-acid manufacturing ecosystem has developed across several connected layers, including upstream raw-material suppliers, specialized CDMO/CRDMO service providers, and regional biopharma industrial clusters. For companies developing mRNA, oligonucleotides, RNA delivery systems, or other nucleic-acid-based therapeutics, the following companies and regions may serve as useful starting points for partner mapping.
Upstream Raw-Material Suppliers and Manufacturing Platforms
Hongene Biotech — Category: Nucleic-acid raw materials; oligonucleotide and mRNA CDMO. Hongene Biotech provides nucleic-acid raw materials such as phosphoramidites, GalNAc-related materials, nucleotides, cap analogs, and enzymes. The company also offers oligonucleotide and mRNA-related CDMO services, making it relevant for developers seeking both upstream materials and manufacturing support. Website: https://www.hongene.com/
Vazyme — Category: mRNA production enzymes and workflow solutions. Vazyme provides enzyme products and workflow solutions for mRNA production, including IVT-related enzymes such as T7 RNA polymerase products, DNase I, and other reagents used in mRNA research, process development, and manufacturing workflows. Website: https://www.vazymeglobal.com/
CDMO and CRDMO Service Providers
Hongene Biotech — Category: Vertically integrated nucleic-acid CDMO. In addition to raw materials, Hongene supports oligonucleotide and mRNA development through CDMO services. Its integrated model may be useful for projects that require raw-material supply, process development, analytical support, and manufacturing within the same nucleic-acid-focused platform. Website: https://www.hongene.com/
WuXi Vaccines — Category: Vaccine CDMO; mRNA vaccine development and GMP manufacturing. WuXi Vaccines provides vaccine development and GMP manufacturing services, including mRNA vaccine-related capabilities. Its services are relevant for developers working on vaccine programs that require CMC development, mRNA-LNP production, aseptic filling, and GMP manufacturing support. Website: https://wuxivaccines.com/
WuXi TIDES — Category: Oligonucleotide, peptide, and synthetic-conjugate CRDMO. WuXi TIDES is a CRDMO platform under WuXi AppTec focused on oligonucleotides, peptides, and related synthetic conjugates. Its services cover discovery synthesis, CMC development, process development, drug-substance manufacturing, and drug-product support for complex synthetic therapeutics. Website: https://tides.wuxiapptec.com/
Asymchem — Category: Oligonucleotide process development and GMP manufacturing. Asymchem provides oligonucleotide development and manufacturing services, including process development, analytical support, GMP drug-substance manufacturing, pre-formulation, and drug-product support. It may be relevant for companies moving oligonucleotide candidates from development-stage chemistry toward scalable manufacturing. Website: https://www.asymchem.com/
Regional Biopharma Industrial Clusters
Regional industrial clusters are another important part of China’s biopharma ecosystem. These clusters bring together companies, research institutions, hospitals, suppliers, service providers, investors, and local policy support within the same geographic regions.
Public reporting on the 2025 China biopharma industrial-park competitiveness assessment identified several leading biopharma clusters, including:
Zhongguancun Demonstration Zone
Suzhou Industrial Park
Shanghai Zhangjiang High-Tech Zone
Chengdu High-Tech Zone
Wuhan East Lake High-Tech Zone
These parks are more than real-estate platforms. They function as local innovation ecosystems that can support company formation, technology translation, talent recruitment, financing, clinical collaboration, and manufacturing scale-up.
For RNA and nucleic-acid companies, these regional clusters may be especially useful because they concentrate multiple resources in one place. A company developing an RNA therapeutic may need raw-material suppliers, CDMO partners, analytical vendors, clinical collaborators, regulatory consultants, and financing support. Industrial clusters can make it easier to access these resources within a coordinated local ecosystem.
Summary
Overall, China’s RNA and nucleic-acid ecosystem now includes upstream raw-material suppliers, specialized CDMO and CRDMO platforms, and regional industrial clusters that support company formation, process development, GMP manufacturing, financing, clinical collaboration, and scale-up. For global developers evaluating Chinese partners, the key considerations should include technical fit, quality systems, regulatory experience, communication efficiency, project-management capability, and the partner’s ability to support the full development path from early research to GMP production.
The companies and regions listed above are representative examples rather than an exhaustive ranking.
